NEW YORK, May 14, 2021 /PRNewswire/ PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of
Galderma Receives FDA Approval for Restylane® Defyne for Chin Augmentation
Represents second approved indication for Restylane Defyne in U.S.; expands Galderma Aesthetics growing Restylane product portfolio
News provided by
Share this article
Share this article
FORT WORTH, Texas, Feb. 2, 2021 /PRNewswire/ Galderma announces that the U.S. Food and Drug Administration (FDA) has approved
Restylane
® Defyne for the augmentation and correction of mild to moderate chin retrusion for adults over the age of 21.
1 In 2020 alone, online searches for chin enhancement increased by 185 percent, reinforcing the emerging patient need for a product like
Restylane Defyne.
2
Restylane Defyne is the first and only chin filler to demonstrate results across a wide range of participants
Galderma Announces Launch of Face for Change Program
Partnerships with Dress for Success and The Skin Cancer Foundation Provide an Opportunity to Give Back with Each Dysport® (abobotulinumtoxinA) for Injection Treatment
News provided by
Share this article
Share this article
FORT WORTH, Texas, Jan. 26, 2021 /PRNewswire/ Galderma has launched Face for Change, a program designed to make a positive impact in communities around the country. This purpose-driven program, in partnership with Dress for Success and The Skin Cancer Foundation, will allow users of
Dysport
(PRNewsfoto/Galderma)
Starting January 19, 2021, and ending February 28, 2021, for every patient who receives a facial aesthetic treatment with